Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?

Milbank Quarterly

Volumn 96, Issue 3, 2018, Pages 499-529

  Fox Rawlings, Stephanie R ^a   Gottschalk, Laura B ^a   Doamekpor, Laurén A ^a   Zuckerman, Diana M ^a  

^a National Center for Health Research   (United States)

Author keywords

clinical trials; device approval; diversity; subgroup analysis; US Food and Drug Administration (FDA)

Indexed keywords

AGE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DEVICE APPROVAL; DEVICE SAFETY; GENDER; HUMAN; PATIENT CARE; PRIORITY JOURNAL; RACE; ADOLESCENT; ADULT; AGED; ANCESTRY GROUP; FEMALE; LEGISLATION AND JURISPRUDENCE; MALE; MIDDLE AGED; MINORITY GROUP; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; DEVICE APPROVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINORITY GROUPS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85053052053     PISSN: 0887378X     EISSN: 14680009     Source Type: Journal    
DOI: 10.1111/1468-0009.12344     Document Type: Article

References (58)

1. Batchelor WB, Ellis SG, Ormiston JA, et al. Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents. J Interv Cardiol. 2013;26(1):49-57. https://doi.org/10.1111/j.1540-8183.2012.00760.x
2. Inacio MCS, Ake CF, Paxton EW, et al. Sex and risk of hip implant failure. JAMA Intern Med. 2013;173(6):435. https://doi.org/10.1001/jamainternmed.2013.3271
3. Yan G, Norris KC, Yu AJ, et al. The relationship of age, race, and ethnicity with survival in dialysis patients. Clin J Am Soc Nephrol. 2013;8(6):953-961. https://doi.org/10.2215/CJN.09180912
4. National Institutes of Health Revitalization Act, Pub L No. 103–43, 107 Stat 102 (1993). https://www.gpo.gov/fdsys/pkg/STATUTE-107/pdf/STATUTE-107-Pg122.pdf. Accessed July 30, 2018
5. US Department of Health & Human Services. Policy Statement on Inclusion of Race and Ethnicity in DHHS Data Collection Activities. Washington, DC: Department of Health and Human Services; October 24, 1997. https://aspe.hhs.gov/policy-statement-inclusion-race-and-ethnicity-dhhs-data-collection-activities. Accessed June 18, 2018
6. US Food and Drug Administration. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Silver Spring, MD: US Food and Drug Administration; 1988. https://www.fda.gov/downloads/Drugs/…/Guidances/UCM071665.pdf. Accessed June 18, 2018
7. US Food and Drug Administration Office of Device Evaluation. Annual Report Fiscal Year 1994. Silver Spring, MD: US Food and Drug Administration; 1995
8. US Food and Drug Administration. Guidance for Industry: E7 Studies in Support of Special Populations; Geriatrics Questions and Answers. Silver Spring, MD: US Food and Drug Administration; 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm189544.pdf. Accessed June 18, 2018
9. US Food and Drug Administration. Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD: US Food and Drug Administration; 2017. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM507278.pdf. Accessed June 18, 2018
10. US Food and Drug Administration. Evaluation of Sex-Specific Data in Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD: US Food and Drug Administration; 2014. https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM283707.pdf. Accessed June 18, 2018
11. Dhruva SS, Cullen EB, Redberg RF. Gender bias in studies for FDA premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011;4:165-171. https://doi.org/10.1007/s12170-014-0389-2
12. Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000–2007. Am J Ther. 2010;17(1):2-7. https://doi.org/10.1097/MJT.0b013e3181ca8105
13. Food and Drug Administration Safety and Innovation Act, Pub L No. 112–144, 126 Stat 993 (2012). https://www.congress.gov/112/plaws/publ144/PLAW-112publ144.pdf. Accessed July 30, 2018
14. US Food and Drug Administration. Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products. Silver Spring, MD: US Food and Drug Administration; 2013
15. US Food and Drug Administration. The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry. Silver Spring, MD: US Food and Drug Administration; 2002. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm085999.pdf. Accessed June 18, 2018
16. US Food and Drug Administration. The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications: Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD: US Food and Drug Administration; 2014. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm284443.pdf. Accessed July 30, 2018
17. US Food and Drug Administration. Guidance for Industry and Food and Drug Administration Staff: Humanitarian Use Device (HUD) Designations. Silver Spring, MD: US Food and Drug Administration; 2013. https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM336515.pdf. Accessed June 18, 2018
18. US Food and Drug Administration. De Novo Classification Process (Evaluation of Automatic Class III Designation): Guidance for Industry and Food and Drug Administration Staff. Silver Spring, MD: US Food and Drug Administration; 2017. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm080197.pdf. Accessed June 18, 2018
19. PMA application contents. US Food and Drug Administration website. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm050289.htm. Published 2018. Accessed May 24, 2018
20. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194. https://doi.org/10.1056/NEJMsr077003
21. Premarket approval (PMA) database. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm. Published 2018. Accessed May 24, 2018
22. United States Food and Drug Administration. FDA Executive Summary: STAAR Surgical Visian Toric Implantable Collamer® Lens. Silver Spring, MD: US Food and Drug Administration; 2014. https://wayback.archive-it.org/7993/20170114045346/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OphthalmicDevicesPanel/UCM385479.pdf. Accessed June 12, 2018
23. KAMRA Inlay: Professional Use Information. Irvine, CA: AcuFocus Inc; 2015. https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120023D.pdf. Accessed June 12, 2018
24. AMPLATZER PFO Occluder: Instructions for Use. Plymouth, MN: St. Jude Medical; 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120021C.pdf. Accessed June 12, 2018
25. US Food and Drug Administration. FDA Executive Summary: Bard LUTONIX 035 Drug Coated Balloon PTA Catheter. Silver Spring, MD: US Food and Drug Administration; 2014. http://wayback.archive-it.org/7993/20170114045515/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM400614.pdf. Accessed June 12, 2018
26. Bard Lutonix Inc. Sponsor Executive Summary: Lutonix Drug Coated Balloon PTA Catheter. New Hope, MN: Bard Lutonix; 2014. http://wayback.archive-it.org/7993/20170114045522/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM400420.pdf. Accessed June 12, 2018
27. US Food and Drug Administration. FDA Executive Summary: Cologuard. Silver Spring, MD: US Food and Drug Administration; 2014. http://wayback.archive-it.org/7993/20170114045719/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM390220.pdf. Accessed June 12, 2018
28. TM SDNA-Based Colorectal Cancer Screening Test. Madison, WI: Exact Sciences Corporation; 2014. http://wayback.archive-it.org/7993/20170114045736/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM390227.pdf. Accessed June 18, 2018
29. US Food and Drug Administration. FDA Executive Summary: Epi ProColon®. Silver Spring, MD: US Food and Drug Administration; 2014. http://wayback.archive-it.org/7993/20170114045715/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM390221.pdf. Accessed June 18, 2018
30. Epigenomics AG. Sponsor Executive Summary: Epi ProColon® Test. Berlin, Germany: Epigenomics AG; 2014. http://wayback.archive-it.org/7993/20170114045728/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM390234.pdf. Accessed June 12, 2018
31. US Food and Drug Administration. FDA Executive Summary: KAMRA Corneal Inlay, Model ACI 7000. Silver Spring, MD: US Food and Drug Administration; 2014. http://wayback.archive-it.org/7993/20170114045310/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OphthalmicDevicesPanel/UCM399638.pdf. Accessed June 18, 2018
32. TM Inlay—Model ACI 7000. Irvine, CA: AcuFocus Inc; 2014
33. Haseltine SJ, Pae J, Ehrlich JR, Shammas M, Radcliffe NM. Variation in corneal hysteresis and central corneal thickness among black, hispanic and white subjects. Acta Ophthalmol. 2012;90(8):626-631. https://doi.org/10.1111/j.1755-3768.2012.02509.x
34. Shimmyo M, Ross AJ, Moy A, Mostafavi R. Intraocular pressure, Goldmann applanation tension, corneal thickness, and corneal curvature in Caucasians, Asians, Hispanics, and African Americans. Am J Ophthalmol. 2003;136(4):603-613. https://doi.org/10.1016/S0002-9394(03)00424-0
35. Mastroianni AC, Faden R, Federman D. Women and health research: a report from the Institute of Medicine. Kennedy Inst Ethics J. 1994;4(1):55-62
36. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA. 2007;297(11):1233. https://doi.org/10.1001/jama.297.11.1233
37. Downing NS, Shah ND, Neiman JH, Aminawung JA, Krumholz HM, Ross JS. Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials. 2016;17(1). https://doi.org/10.1186/s13063-016-1322-4
38. Eshera N, Itana H, Zhang L, Soon G, Fadiran EO. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA from 2010 to 2012. Am J Ther. 2015;22(6):435-455. https://doi.org/10.1097/MJT.0000000000000177
39. Colby SL, Ortman JM. Projections of the Size and Composition of the US Population: 2014 to 2060. Washington, DC: US Census Bureau; 2014. http://www.census.gov/content/dam/Census/library/publications/2015/demo/p25-1143.pdf. Accessed June 18, 2018
40. Dhruva SS, Mazure CM, Ross JS, Redberg RF. Inclusion of demographic-specific information in studies supporting US Food and Drug Administration approval of high-risk medical devices. JAMA Intern Med. 2017;177(9):1390. https://doi.org/10.1001/jamainternmed.2017.3148
41. US Food and Drug Administration. FDA Report: FDA Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data. Silver Spring, MD: US Food and Drug Administration; 2014. http://www.fda.gov/downloads/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/UCM410474.pdf. Accessed June 18, 2018
42. US Food and Drug Administration. Collection, Analysis & Availability of Demographic Subgroup Data Public Meeting, April 1, 2014 [transcript]. http://wayback.archive-it.org/7993/20170111191045/http://www.fda.gov/downloads/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/UCM397391.pdf. Accessed June 12, 2018
43. FDA's action plan for FDASIA Section 907: questions and answers. US Food and Drug Administration website. https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/ucm410382.htm. Published March 2018. Accessed May 24, 2018
44. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):136-143. https://doi.org/10.1513/pats.200709-155MG
45. Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. Prog Cardiovasc Dis. 2009;51(4):285-293. https://doi.org/10.1016/j.pcad.2008.08.001
46. US Food and Drug Administration. Inspire Upper Airway Stimulation (UAS) System: Executive Summary. 2014. https://wayback.archive-it.org/7993/20170114045750/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/AnesthesiologyandRespiratoryTherapyDevicesPanel/UCM386160.pdf. Accessed June 20, 2018
47. Inspire Medical Systems Inc. Sponsor Executive Summary: Inspire Upper Airway Stimulation (UAS) System. Maple Grove, MN: Inspire Medical Systems Inc; 2014. https://wayback.archive-it.org/7993/20170114045755/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/AnesthesiologyandRespiratoryTherapyDevicesPanel/UCM386164.pdf. Accessed June 20, 2018
48. Inspire Upper Airway Stimulation (UAS): System Implant Manual. Maple Grove, MN: Inspire Medical Systems; 2014. http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008D.pdf. Accessed June 12, 2018
49. US Food and Drug Administration; Center for Devices and Radiological Health; Medical Devices Advisory Committee. Circulatory System Devices Panel, June 12, 2014 [transcript]. http://wayback.archive-it.org/7993/20170114045519/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM404388.pdf. Accessed June 12, 2018
50. LUTONIX ® 035 Drug Coated Balloon PTA Catheter: Instructions for Use. New Hope, MN: Bard Lutonix Inc; 2013. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130024D.pdf. Accessed June 20, 2018
51. US Food and Drug Administration; Center for Devices and Radiological Health; Medical Devices Advisory Committee. Molecular and Clinical Genetics Panel, March 26, 2014 [transcript]. http://wayback.archive-it.org/7993/20170114045726/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MolecularandClinicalGeneticsPanel/UCM395028.pdf. Accessed June 12, 2018
52. Epi proColon® Test [labeling]. Berlin, Germany: Epigenomics AG; 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf. Accessed July 20, 2018
53. Post-approval studies: Epi proColon. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?c_id=3927&t_id=505162. Accessed June 22, 2018
54. Zuckerman D, Brown P, Das A. Lack of publicly available scientific evidence on the safety and effectiveness of implanted medical devices. JAMA Intern Med. 2014;174(11):1781-1787. https://doi.org/10.1001/jamainternmed.2014.4193
55. US Government Accountability Office. Report to the Ranking Member, Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, Committee on Appropriations, House of Representatives: Medical Devices—FDA Ordered Postmarket Studies to Better Understand Safety Issues, and Many Studies Are Ongoing. Washington, DC: US Government Accountability Office; 2015. https://www.gao.gov/assets/680/672860.pdf. Accessed June 18, 2018
56. Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011. JAMA. 2015;314(6):604. https://doi.org/10.1001/jama.2015.8761
57. Reynolds IS, Rising JP, Coukell AJ, Paulson KH, Redberg RF. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies. JAMA Intern Med. 2014;174(11):1773-1779. https://doi.org/10.1001/jamainternmed.2014.4194
58. Buch BD. Recent progress on demographic information and clinical trials. FDA Voice. blogs.fda.gov/fdavoice/index.php/2015/02/recent-progress-on-demographic-information-and-clinical-trials. Published 2015. Accessed June 12, 2018